Supernus Pharmaceuticals (SUPN) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Supernus Pharmaceuticals (SUPN), with a price target of $57. The company’s shares closed yesterday at $41.65.

Tanner noted:

“: We reiterate the Overweight rating and raise our 12-month PT to $57 from $56 on SUPN stock. We maintain our belief that the next 6-12 months will be an important period for the company insofar as the potential identification of out-year top- and bottom-line growth drivers is concerned.”

According to, Tanner is a 2-star analyst with an average return of 0.7% and a 43.3% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Evofem Biosciences Inc, and Amag Pharmaceuticals.

Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $57.60, representing a 38.3% upside. In a report issued on October 29, Mizuho Securities also reiterated a Buy rating on the stock with a $61 price target.


See today’s analyst top recommended stocks >>

Supernus Pharmaceuticals’ market cap is currently $2.17B and has a P/E ratio of 25.87. The company has a Price to Book ratio of 5.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.